Morgan Stanley raised the firm’s price target on Neurocrine (NBIX) to $168 from $163 and keeps an Overweight rating on the shares ahead of the Q3 report due on Tuesday, October 28. The firm thinks investor focus will be on Crenessity launch metrics in the second half and Ingrezza’s performance, the analyst says in a preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Positive Outlook for Neurocrine Biosciences Amidst Strong Prescription Growth and Strategic Positioning
- Neurocrine presents new data from Phase 3, open-label KINECT 4 study
- Neurocrine price target raised to $195 from $188 at UBS
- Neurocrine presents new data from KINECT-HD2 study of ingrezza
- Neurocrine’s ingrezza shows efficacy in tardive dyskinesia